https://www.selleckchem.com/products/plx5622.html
Nivolumab is Food and Drug Administration approved in sorafenib-experienced, advanced hepatocellular carcinoma (HCC). Post-registration data of treatment in a real-world setting is lacking. We performed an international, multicenter observational study to confirm safety and efficacy of nivolumab in 233 patients treated outside clinical trials from eight centers in North America, Europe and Asia. Patients received nivolumab for Barcelona Clinic Liver Cancer stage C (n 191, 92.0%) and Child-Pugh (CP) A (n 158, 67.8%) or B (n 75, 32.2%) HC
Like
Comment
Share
